24-25 novembre 2023

CONGRESSO ATBV 2023

Filmati dei lavori

 

I giornata

WHAT IS THE OPTIMAL STRATEGY FOR LDL-C REDUCTION AFTER AN ACUTE MYOCARDIAL INFARCTION?

Moderatori: Leonardo De Luca, Alberto Margonato

 

Position #1: PCSK9-I with Monoclonal Antibodies Remains the Standard – Giuseppe Patti

Position #2: The siRNA Approach with Inclisiran Will Take Over – Pierfranco Terrosu

Position #3: Bempedoic acid: More than Just an Alternative to PCSK9-I – Paolo Calabrò

 

 

INFLAMMATION: THE NEXT ACTIONABLE TARGET IN PATIENTS WITH CARDIOVASCULAR AND RENAL DISEASE?

Moderatori: Pasquale Perrone Filardi, Claudio Fresco

 

Colchicine and Beyond: emerging targets in inflammation in patients to acute and chronic coronary syndrome use – Massimo Imazio

Interleukin-1 and Interleukin-6 inhibition – Roberto Pontremoli

State of the Art Lecture: Inflammation and Immunity as Targets in Cardiovascular and Renal Diseases – Raffaele De Caterina

 

II giornata

 

ANTITHROMBOTIC STRATEGIES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE

Moderatori: Leonardo Bolognese, Luigi Maria Oltrona Visconti

 

Is Aspirin Over for Primary Prevention? – Bianca Rocca

Chronic Antiplatelet Monotherapy in Coronary Artery Disease: P2Y12-I or Aspirin? – Felice Gragnano

Antithrombotic Management of Peripheral Artery Disease: A Complex Mosaic – Davide Capodanno

State-of-the-Art Lecture: The End of the «DAPT era» – Marco Valgimigli